New Medtronic Data Demonstrate Clinical and Quality of Life Benefits for VenaSeal Closure System in Venous Reflux Disease Patients

VERITAS Vision System Is Introduced by Johnson & Johnson

The company will offer live demos of the new system in a wet lab at the Johnson & Johnson booth (#2813) this weekend at the 2021 American Society of Cataract and Refractive Surgery and American Society of Ophthalmic Administrators Annual Meeting.

GenesisCare Orders 27 Elekta Flexitron Treatment Devices

"GenesisCare continues to demonstrate its commitment to improving patient outcomes worldwide and Elekta is delighted to play a vital partnering role to achieve this mission," said Gustaf Salford, Elekta's President and CEO.

FoodMarble AIRE Shown to Exceed the Performance of ‘Gold Standard’ SIBO Testing in Clinical Trial

SIBO is a very common disorder where there are excessive bacteria present in the small intestine. The true prevalence of SIBO in the general population is largely unknown, with some studies estimating its occurrence in up to 15% of healthy individuals. It is also largely associated with many other common clinical conditions, including irritable bowel syndrome, where 40-80% of IBS patients have SIBO.

April 25, 2017

Medtronic plc today announced three-year outcomes from the VeClose U.S. pivotal clinical trial and one-year data from the WAVES study. Both results were presented by Kathleen Gibson, M.D., of Lake Washington Vascular in Bellevue, Wash., at the 2017 Charing Cross Symposium in London.

Medtronic notes the new data demonstrate the clinical and quality of life benefits of the Medtronic VenaSeal(TM) closure system in treating patients with venous reflux disease.

Three-Year Data from VeClose Trial
The VeClose U.S. pivotal clinical trial is a prospective, randomized, controlled trial comparing the safety and effectiveness of the VenaSeal closure system to the Medtronic ClosureFast(TM) endovenous radiofrequency ablation (RFA) procedure in a non-inferiority design. The trial enrolled 242 patients with symptomatic refluxing great saphenous veins (GSV), of which 222 were randomized 1:1 to receive treatment with VenaSeal or ClosureFast.

At three-years, the complete closure of the GSV was achieved in 94.4 percent of patients treated with VenaSeal compared to 91.9 percent of patients treated with ClosureFast – showing both the continued long-term, non-inferior outcomes (p=0.005) and the durability of the treatment.

Additionally, patient improvement was rated on three assessments: Venous Clinical Severity Score (VCSS), a clinical venous disease assessment; and the Aberdeen Varicose Vein Questionnaire (AVVQ) and EQ-5D – both of which provide patient-reported quality of life scores. In all three assessments, patients treated with either VenaSeal or ClosureFast reflected statistically significant improvement from baseline.

“The three-year outcomes for this randomized trial reinforce the consistent clinical performance of VenaSeal and ClosureFast,” said Dr. Gibson. “These long-term VenaSeal data along with post-market WAVES study results continue to build on the prior findings for this innovative treatment option for venous reflux disease, demonstrating safety, effectiveness, and quality of life.”

One-Year WAVES Study Data Presented for the First Time
In a separate session at Charing Cross, Dr. Gibson presented the one-year data from the independent, physician-initiated WAVES study, demonstrating quality of life impacts along with safety and effectiveness of the VenaSeal closure system. The single-center study enrolled 50 patients in a real-world assessment of the treatment of one or more incompetent truncal veins in a single setting without mandatory post-operative compression stockings.

Key findings from the WAVES study are summarized as follows:

  • The one-year GSV closure rate for VenaSeal was 100 percent. In comparison, the GSV closure rate for VenaSeal in VeClose, which required post-operative compression stockings, was 96.8 percent. Further, the mean vessel diameter in WAVES was larger than in VeClose.
  • The mean time for patients’ return to work was 0.2 days ± 1.1 days. Furthermore, the mean time for returning to normal activities, including a patient’s exercise routine, was 2.4 days ± 4.1 days.

“The data presented at Charing Cross further demonstrate the VenaSeal closure system as a safe and effective therapy for treating venous reflux disease,” said Sandra Lesenfants, vice president and general manager of the endoVenous business, which is part of the Cardiac and Vascular Group at Medtronic. “Together with the clinical community, we look forward to continuing our investment in clinical research to support the use of this innovative, minimally invasive treatment for venous reflux disease.”

spot_img

DON'T MISS

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.